Eli Lilly’s drug tyrzepatide, which is expected to get FDA approval this year, has been shown to reduce subjects’ body weight by an average of 22.5%. (Reuters)
[Notizie istantanee/Rapporto completo]Tirzepatide, Eli Lilly Pharmaceutical Company’s drug (Eli Lilly) for the treatment of adults with type 2 diabetes, was approved by the US Food and Drug Administration (FDA) last year and is expected to be approved again this year for weight In phase 3 studies, the drug can reduce subjects’ body weight by an average of 22.5%, which is better than various diet drugs currently on the market.
according to”NBC“Eli Lilly’s tyrzepatide reported to be similar to Novo Nordisk’s popular weight-loss drugs Wegovy and Saxenda. 1), helps reduce appetite and reduce dietary intake.
However, tyrzepatide also mimics gastric inhibitory peptide (GIP), which can improve the way the body breaks down sugar and fat by reducing appetite. In experiments where most subjects had a BMI of 30 or more, Wegovy and Saxenda lost 15% and 5% of body weight, respectively, and tyrzepatide achieved 22.5%.
Eli Lilly spokesman Kelly Smith (Kelly Smith) refused to explain the price of tyrzepatide. Medical experts believe it may be similar to Novo Nordisk’s drug, i.e. Wegovy is priced at US$1,500 (about NT$46,000) per month , or Saxenda is priced at US$1,350 (about NT$41,000) per month.
The Clinical and Economic Review Agency, which helps set fair prices for the drugs, has pointed out that if tyrzepatide is approved by the FDA for weight loss, the price could be US$13,000 (about NT$400,000) a year , or US$1,100 (about NT$3.30) per month million yuan).
Bank of America analysts estimate that tyrzepatide could reach US$48 billion (about NT$1,474.3 billion) in annual sales as a weight-loss drug. UBS analysts estimated it at US$25 billion (about NT$767.8 billion), although the latter forecast was lower, but it still surpassed the drug’s record of US$20.7 billion for the rheumatoid arthritis AbbVie’s Humira in 2021 (about NT $ 635.8 billion), and became the record the best-selling drug in history.
However, it is likely that the US insurance industry will not cover tyrzepatide as a dietary drug, or there will be many restrictions, which means that patients will face the situation of buying tyrzepatide out of pocket, which will be a huge expense burden, and perhaps only wealthy families can afford it.
☆ Health news will never miss, the press loves to keep trackfan page。
☆For more important medical news, go toFreedom Health Network。
No need to smoke, no rush, now use the APP to watch the news and guarantee to win the lottery every dayClick me to download the APP
According to how I see the activities
